Clay-based hemostatic agents and devices for the delivery thereof
View Patent ↗A hemostatic device for promoting the clotting of blood includes a gauze substrate, a clay material disposed on the gauze substrate, and also a polyol such as glycerol or the like disposed on the gauze substrate to bind the clay material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood emanating from the wound to cause the clotting. A bandage that can be applied to a bleeding wound to promote the clotting of blood includes a flexible substrate and a gauze substrate mounted thereon. The gauze substrate includes a clay material and a polyol. A hemostatic sponge also includes a gauze substrate and a dispersion of hemostatic material and a polyol on a first surface of the substrate.
1. A device capable of providing a hemostatic effect on bleeding, said device comprising:
a gauze substrate;
a clay material disposed on said gauze substrate; and
a water-soluble polyol binder disposed on said gauze substrate to bind said clay material to said gauze substrate;
wherein the gauze substrate initially exists separately from the clay material before the gauze and the clay material are combined;
wherein the polyol binder has an effect of substantially suppressing clay dust; and
wherein said device is not saturated with a liquid and the device is configured such that when treating bleeding, application of said device is capable of causing at least a portion of said clay material to come into contact with blood to assist in accelerating cloning.
2. The device of claim 1 , wherein said clay material is kaolin.
3. The device of claim 1 , wherein said clay material is selected from the group consisting of attapulgite, bentonite, kaolin, and combinations of the foregoing materials.
4. The device of claim 1 , further comprising diatomaceous earth disposed on said gauze substrate.
5. The device of claim 1 , wherein said clay material further comprises a material selected from the group consisting of magnesium sulfate, sodium metaphosphate, calcium chloride, dextrin, hydrates of the foregoing materials, and combinations of the foregoing materials.
6. The device of claim 1 , further comprising a pharmaceutically-active composition selected from the group consisting of antibiotics, antifungal agents, antimicrobial agents, anti-inflammatory agents, analgesics, antihistamines, compounds containing silver or copper ions, and combinations of the foregoing compositions.
7. The device of claim 1 , wherein said gauze substrate is fabricated from a material selected from the group consisting of cotton, silk, wool, plastic, cellulose, rayon, polyester, and combinations of the foregoing.
8. The device of claim 1 , wherein said gauze substrate is flexible to allow said gauze substrate to form to a shape of said bleeding wound and to retain a shape of said bleeding wound.
9. The device of claim 1 , wherein said clay material is dispersed in said polyol and disposed on said substrate.
10. The device of claim 1 , further comprising a release agent disposed on said clay material.
11. The device of claim 10 , wherein said release agent is selected from the group consisting of polyvinyl alcohol, glycerol, silicone, carboxymethyl cellulose, and gelatinized starch.
12. The device of claim 10 , wherein said release agent is a film formed over said clay material.
13. The device of claim 1 , wherein said clay material comprises particles having diameters of about 0.2 mm to about 10 mm.
14. The device claim 1 , wherein said clay material comprises particles having diameters of about 1 mm to about 7 mm.
15. The device of claim 1 , wherein said clay material comprises particles having diameters of about 2 mm to about 5 mm.
16. The device of claim 1 , wherein said clay material comprises particles having diameters of less than 0.2 mm.
17. The device of claim 1 , wherein said polyol is selected from the group consisting of glycerol, glycerol-based compounds, sorbitol, xylitol, maltol, polymeric polyols, and combinations of the foregoing.
18. The device of claim 17 , wherein said polymeric polyol is polydextrose.
19. The device of claim 17 , wherein said glycerol-based compound is selected from the group consisting of propylene glycols, glyceryl triacetates, and combinations of the foregoing.
20. A bandage applicable to a bleeding wound, said bandage comprising:
a flexible substrate;
a gauze substrate mounted on said flexible substrate; a clay material disposed on said gauze substrate; and
a water-soluble polyol binder disposed on said gauze substrate to bind said clay material to said gauze substrate;
wherein the gauze substrate initially exists separately from the clay;
wherein the polyol binder has an effect of substantially suppressing clay dust; and
wherein said device is dry in that it is not saturated with a liquid and the device is configured such that when treating bleeding, application of said bandage is capable of causing at least a portion of said clay material to come into contact with blood to assist in accelerating cloning.
21. The bandage of claim 20 , wherein said clay material is kaolin.
22. The bandage of claim 20 , wherein said clay material is selected from the group consisting of attapulgite, bentonite, kaolin, and combinations of the foregoing materials.
23. The bandage of claim 20 , wherein said clay material further comprises a material selected from the group consisting of magnesium sulfate, sodium metaphosphate, calcium chloride, dextrin, hydrates of the foregoing materials, and combinations of the foregoing materials.
24. The bandage of claim 20 , further comprising a pharmaceutically-active composition selected from the group consisting of antibiotics, antifungal agents, antimicrobial agents, anti-inflammatory agents, analgesics, antihistamines, compounds containing silver ions, and combinations of the foregoing compositions.
25. The bandage of claim 20 , further comprising an adhesive on said substrate, said adhesive being configured to facilitate the retaining of said bandage on the skin of a wearer.
26. The bandage of claim 20 , wherein said clay material is dispersed in said polyol and disposed on said gauze substrate.
27. The bandage of claim 20 , wherein said polyol is selected from the group consisting of glycerol, glycerol-based compounds, sorbitol, xylitol, maltol, polymeric polyols, and combinations of the foregoing.
28. The bandage of claim 27 , wherein said glycerol-based compound is selected from the group consisting of propylene glycols, glyceryl triacetates, and combinations of the foregoing.
29. The bandage of claim 20 , further comprising a release agent disposed over said clay material and said polyol disposed on said gauze substrate.
30. The bandage of claim 29 , wherein said release agent is selected from the group consisting of polyvinyl alcohol, glycerol, silicone, carboxymethyl cellulose, and gelatinized starch.
31. A hemostatic sponge, comprising:
a gauze substrate having a first surface; and
a dispersion of a hemostatic clay material and a water-soluble polyol binder disposed on said first surface of said gauze substrate;
wherein the gauze substrate is provided separately from the clay when the sponge is made;
wherein the polyol binder has an effect of substantially suppressing clay dust; and
wherein said device is dry in that it is not saturated with a liquid and the device is configured such that when treating bleeding, application of said hemostatic sponge is capable of causing at least a portion of said hemostatic material to come into contact with blood to assist in accelerating clotting.
32. The hemostatic sponge of claim 31 , further comprising a release agent disposed on at least one of said gauze substrate and said dispersion of hemostatic material and polyol.
33. The hemostatic sponge of claim 31 , wherein said hemostatic material is kaolin.
34. The hemostatic sponge of claim 31 , wherein said hemostatic material is selected from the group consisting of attapulgite clay, bentonite clay, kaolin clay, bioactive glass, biological hemostats, diatomaceous earth, and combinations of the foregoing.
35. The hemostatic sponge of claim 32 , wherein said release agent is selected from the group consisting of polyvinyl alcohol, glycerol, silicone, carboxymethyl cellulose, and gelatinized starch.
36. The hemostatic sponge of claim 31 , wherein said polyol is selected from the group consisting of glycerol, glycerol-based compounds, sorbitol, xylitol, maltol, polymeric polyols, and combinations of the foregoing.
37. The hemostatic sponge of claim 36 , wherein said glycerol-based compound is selected from the group consisting of propylene glycols, glyceryl triacetates, and combinations of the foregoing.
38. A hemostatic sponge, comprising:
a first substrate;
a hemostatic material dispersed in a water soluble polyol binder and applied to said first substrate; and
a second substrate disposed on said hemostatic material dispersed in said polyol;
wherein said device is dry in that it is not saturated with a liquid and the device is configured such that when treating a bleeding wound, application of said hemostatic sponge is capable of causing at least a portion of said hemostatic material to come into contact with blood through at least one of said first substrate and said second substrate.
39. The hemostatic sponge of 38 , claim wherein said hemostatic material is selected from the group consisting of attapulgite clay, bentonite clay, kaolin clay, bioactive glass, biological hemostats, diatomaceous earth, and combinations of the foregoing.
40. The hemostatic sponge of claim 38 , further comprising a release agent disposed on said hemostatic material dispersed in said polyol.
41. The hemostatic sponge of claim 40 , wherein said release agent is selected from the group consisting of polyvinyl alcohol, glycerol, silicone, carboxymethyl cellulose, and gelatinized starch.
42. The hemostatic sponge of claim 38 , wherein said polyol is selected from the group consisting of glycerol, glycerol-based compounds, sorbitol, xylitol, maltol, polymeric polyols, and combinations of the foregoing.
43. The hemostatic sponge of claim 42 , wherein said glycerol-based compound is selected from the group consisting of propylene glycols, glyceryl triacetates, and combinations of the foregoing.